Page last updated: 2024-11-05

3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole and Colorectal Cancer

3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole has been researched along with Colorectal Cancer in 1 studies

3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole: antineoplastic; activates platelet guanylate cyclase; a radiosensitizing agent and guanylate cyclase activator; structure in first source
lificiguat : A member of the class of indazoles that is 1H-indazole which is substituted by a benzyl group at position 1 and a 5-(hydroxymethyl)-2-furyl group at position 3. It is an activator of soluble guanylate cyclase and inhibits platelet aggregation.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lin, YC1
Chen, YF1
Tseng, LS1
Lee, YH1
Morris-Natschke, SL1
Kuo, SC1
Yang, NS1
Lee, KH1
Huang, LJ1

Other Studies

1 other study available for 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole and Colorectal Cancer

ArticleYear
Synthesis and structure-activity relationship studies of novel 3,9-substituted α-carboline derivatives with high cytotoxic activity against colorectal cancer cells.
    European journal of medicinal chemistry, 2016, Mar-03, Volume: 110

    Topics: Antineoplastic Agents; Apoptosis; Carbolines; Cell Line, Tumor; Cell Proliferation; Colon; Colorecta

2016